top of page
Image by National Cancer Institute

Publications

01

Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2-Positive Breast Cancer and Other Solid Tumors

Ophelia Yin, Yuan Xiong, Seiko Endo, Kazutaka Yoshihara, Tushar Garimella, Malaz AbuTarif, Russ Wada, and Frank LaCreta | Clinical Pharmacology and Therapeutics. 2021 May.

02

Selinexor population pharmacokinetic and exposure-response analyses to support dose optimization in patients with diffuse large B-cell lymphoma

Hongmei Xu, Hanbin Li, Russ Wada, Justin C. Bader, Shijie Tang, Jatin Shah, and Sharon Shacham | Cancer Chemotherapy and Pharmacology. 2021 July.

03

Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan

Ophelia Yin, Hiroji Iwata, Chia-Chi Lin, Kenji Tamura, Junichiro Watanabe, Russ Wada, Helen Kastrissios, Malaz AbuTarif, Tushar Garimella, Caleb Lee, Lin Zhang, Javad Shahidi, and Frank LaCreta | Clinical Pharmacology and Therapeutics. 2021 Oct.

bottom of page